



Announcement Summary

**Entity name**

ARGENT BIOPHARMA LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday February 10, 2026

**The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

Securities issued as consideration for purchase order reimbursement. Securities issued concurrently with approval, as such, an Appendix 3B was not deemed necessary.

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
RGT	ORDINARY FULLY PAID	2,557,450	10/02/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

ARGENT BIOPHARMA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ACN

**Registration number**

116800269

**1.3 ASX issuer code**

RGT

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

10/2/2026



## Part 2 - Type of Issue

---

### **2.1 The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

### **2.2 The +class of +securities to be quoted is:**

Additional +securities in a class that is already quoted on ASX ("existing class")

### **2.3c Have these +securities been offered under a +disclosure document or +PDS?**

No

**2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

Securities issued as consideration for purchase order reimbursement. Securities issued concurrently with approval, as such, an Appendix 3B was not deemed necessary.

**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

---

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

RGT : ORDINARY FULLY PAID

**Issue date**

10/2/2026

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Issue details

---

**Number of +securities to be quoted**

2,557,450

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Securities issued as consideration for purchase order reimbursement.

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

0.100000

**Any other information the entity wishes to provide about the +securities to be quoted**

**The purpose(s) for which the entity is issuing the securities**

Other

**Please provide additional details**

Securities issued as consideration for purchase order reimbursement.

---





## Part 4 - Issued capital following quotation

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
RGT : ORDINARY FULLY PAID	86,942,317

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
RGTAO : WARRANTS EXPIRING 16-JAN-2028 EX USD 0.55	2,500,000
RGTAAM : OPTION EXPIRING 28-MAR-2027 EX \$0.42	240,000
RGTAAI : OPTION EXPIRING 31-JUL-2026 EX \$3.00	181,422
RGTAAL : OPTION EXPIRING 10-JAN-2027 EX \$1.00	740,000
RGTAAB : OPTION EXPIRING 01-APR-2029 EX \$0.70	724,000
RGTAO : WARRANTS EXPIRING 17-JUL-2027 EX USD 1.20	1,250,000
RGTAAP : WARRANT EXPIRING 23-APR-2028 EX USD 0.40	5,500,000
RGTAAQ : OPTION EXPIRING 23-APR-2032 EX USD 0.20	16,500,000
RGTAAN : WARRANTS EXPIRING 03-JUL-2027 EX USD 1.20	312,500
RGTAG : PERFORMANCE RIGHTS	600,000
RGTAAA : CONVERTIBLE NOTES	8,900,032
RGTA AJ : OPTION EXPIRING 07-NOV-2028 EX US\$0.32	15,500,000
RGTA AH : OPTION EXPIRING 14-JUL-2026 EX GBP 1.2	540,668
RGTA A : OPTION EXPIRING 03-DEC-2028 EX \$0.1025	21,950,952



RGTAAK : OPTION EXPIRING 01-DEC-2028 EX \$0.86

288,185



Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

2,557,450 ordinary shares.

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

N/A